Trials / Completed
CompletedNCT00087763
Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)
A Phase II Prospective, Randomized, Double-Masked, Sham-Controlled, Dose-Ranging, Multi-Center Trial to Assess the Effect of Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 135 (planned)
- Sponsor
- Eyetech Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.
Detailed description
This will be a randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups. Patients will be stratified by clinical center and foveal thickness to be treated either Macugen or a sham injection. After 24 weeks, all patients will treated with Macugen until the end of the study at 54 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Macugen ™ (pegaptanib sodium injection) |
Timeline
- Start date
- 2004-03-01
- Completion
- 2006-05-01
- First posted
- 2004-07-16
- Last updated
- 2006-05-03
Source: ClinicalTrials.gov record NCT00087763. Inclusion in this directory is not an endorsement.